Evidence map›Paper›PMID 21960214›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2012

Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease.

Byoung Dae Lee, Xiaojie Li, Ted M Dawson, Valina L Dawson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. New Frontiers in Parkinson's Disease: From Genetics to the Clinic.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Byoung Dae LeeNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xiaojie Li
Ted M Dawson
Valina L Dawson
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Understanding Mechanisms of a-synuclein pathologyP50NS038377 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KO, HANSEOK · 1998 to 2019
$38.8M
The Role of Parkin in Parkinson's DiseaseR01NS048206 · NINDS · JOHNS HOPKINS UNIVERSITY · PI DAWSON, TED M. · 2004 to 2009
$2.0M
NINDS NIH HHS P50 NS038377NINDS NIH HHS P50NS038377NINDS NIH HHS R01 NS048206NINDS NIH HHS R01NS048206
6 · The paper itself

Abstract

Mutations in the LRRK2 (Leucine-Rich Repeat Kinase 2) gene are the most common cause of autosomal dominant Parkinson's disease. LRRK2 has multiple functional domains including a kinase domain. The kinase activity of LRRK2 is implicated in the pathogenesis of Parkinson's disease. Developing an assay to understand the mechanisms of LRRK2 kinase activity is important for the development of pharmacologic and therapeutic applications. Here, we describe how to measure in vitro LRRK2 kinase activity and its inhibition.

Indexed as

Cell Line, TransformedEnzyme ActivationEnzyme AssaysGene Expression RegulationHEK293 CellsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Myelin Basic ProteinParkinson DiseasePhosphorylationProtein Serine-Threonine KinasesRecombinant Fusion ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanMyelin Basic ProteinProtein Serine-Threonine KinasesRecombinant Fusion Proteins

Identifiers

PMID21960214
PMCPMC4433534
OpenAlexW2415908252

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.